tpα

Rp-dGTPαS, an enantiomer of the dNTPαS nucleotide, serves as the substrate for SAMHD1, a critical regulator of cellular dNTP levels that curtails the replication of viruses (HIV-1, etc.) in CD4+ myeloid lineage and resting T cells. The SAMHD1 tetrameric complex facilitates the hydrolysis of Rp-dGQTPαS into 2'-deoxynucleosides and triphosphates [1].

Sp-TTPαS is a competitive inhibitor of the catalytic activity of sterile alpha motif and HD domain containing protein 1 (SAMHD1). It competitively inhibits TTP hydrolysis, with a Ki value of 46 µM.

dATPαS sodium is a labeled and modified deoxyoligonucleotide (dNTP) that releases pyrophosphate to produce fluorescence, offering unique applications in gene synthesis and sequencing.

dTTPαS sodium is a labeled and modified deoxyoligonucleotide (dNTP) that can release pyrophosphate and generate fluorescence during gene synthesis and sequencing, so it has special application value.

dCTPαS sodium is a labeled and modified deoxyoligonucleotide (dNTP) that can release pyrophosphate and generate fluorescence during gene synthesis and sequencing, so it has special application value.

dGTPαS sodium is a labeled and modified deoxyoligonucleotide (dNTP) that can release pyrophosphate and generate fluorescence during gene synthesis and sequencing, so it has special application value.

TPα and TPβ are two isoforms of the human TP receptor, the G protein-coupled receptor (GPCR) that mediates the actions of thromboxane A2 (TXA2). Although their distinct physiological functions have not been fully elucidated, TPβ is believed to be responsible for vascular endothelial growth factor-induced endothelial cell differentiation and migration whereas TPα appears to be the predominant isoform expressed in platelets. CAY10535 is a TP receptor antagonist that shows ~20-fold selectivity for TPβ (IC50 = 99 nM) relative to TPα (IC50 = 1,970 nM) in the inhibition of U46619-mediated Ca2+ mobilization. This compound exhibits relatively poor activity on platelets (IC50 = 985 nM) when inhibiting U-46619-induced platelet aggregation.

TP Receptor Antagonist-2 (example 7n), a thromboxane A2 receptor (TP receptor) antagonist, exhibits inhibitory activity with IC50 values of 5.64 μM for TPα and 5.27 μM for TPβ. It effectively inhibits platelet aggregation [1].